Gilead Sciences Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 3/10/2026)
| Balance Sheet | Total Assets | 59,023,000,000.00 | ROE | 38.32 % |
| Balance Sheet | Total Equity | 22,618,000,000.00 | ROA | 14.42 % |
| Cashflow | Capital Expenditures | -563,000,000.00 | P/FCF | 20.38 |
| Cashflow | Free Cash Flow | 9,456,000,000.00 | – | – |
| Cashflow | Operating Cash Flow | 10,019,000,000.00 | P/CF | 19.23 |
| Income | Earnings per Share (diluted) | 6.78 | Div. Yield | 2.06 % |
| Income | Net Income | 8,510,000,000.00 | P/E | 22.65 |
| Income | Shares Outstanding | 1,255,000,000.00 | P/B | 8.52 |
| Income | Total Revenue | 29,443,000,000.00 | P/S | 6.54 |
Ratios calculated on: 10/14/2026
Company Description
Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead's primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific. The Company's products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera, Letairis, Ranexa, Lexiscan/Rapiscan, AmBisome, Vistide, Macugen, Cayston and Tamiflu. In January 2012, the Company acquired Pharmasset, Inc. On February 8, 2013, its subsidiary, acquired YM BioSciences Inc.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.gilead.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more